Table 1.
Participants’ characteristics and reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine.
| No. (%) |
||
|---|---|---|
| Dose 1 (n = 3254) | Dose 2 (n = 3165) | |
| No. of recipients | 3381 | 3354 |
| No. of respondents | 3254 (96.2) | 3165 (94.4) |
| Demographic characteristics | .. | .. |
| Age Groups | ||
| ≤29 | 1178 (36.2) | 1132 (35.8) |
| 30–39 | 953 (29.3) | 926 (29.3) |
| 40–49 | 632 (19.4) | 624 (19.7) |
| 50–59 | 329 (10.1) | 324 (10.2) |
| 60–69 | 138 (4.2) | 137 (4.3) |
| ≥70 | 24 (0.8) | 22 (0.7) |
| Sex | .. | .. |
| male | 1116 (34.3) | 1091 (34.5) |
| female | 2138 (65.7) | 2074 (65.5) |
| Occupation | ||
| doctor | 926 (28.5) | 899 (28.4) |
| nurse | 1162 (35.7) | 1129 (35.7) |
| pharmacist | 100 (3.1) | 100 (3.2) |
| administrative staff | 1066 (32.8) | 1037 (32.8) |
| Reactogenicity | .. | .. |
| Any | 3165 (97.3) | 3077 (97.2) |
| Injection site reactions (any) | 2972 (91.3) | 2915 (92.1) |
| pain | 2908 (89.4) | 2736 (87.3) |
| swelling | 1001 (30.8) | 1359 (42.9) |
| burning sensation | 930 (28.6) | 1194 (37.7) |
| redness | 494 (15.2) | 840 (26.5) |
| induration | 545 (16.7) | 606 (19.1) |
| itching | 327 (10.0) | 514 (16.2) |
| Systemic reactions (any) | 2445 (75.1) | 2748 (86.8) |
| fatigue | 901 (27.7) | 2304 (72.8) |
| myalgia (muscle ache) | 2132 (65.5) | 2035 (64.3) |
| headache | 463 (14.2) | 1447 (45.7) |
| fever | 95 (2.9) | 1354 (42.8) |
| - low-grade fever (≥37.5°C, but < 38.0°C) | 70/95 (73.7) | 757/1354 (55.9) |
| - high-grade fever (≥38.0°C) | 25/95 (26.3) | 597/1354 (44.1) |
| chills | 119 (3.7) | 1180 (37.3) |
| joint pain | 198 (6.1) | 1092 (34.5) |
| nasal discharge | 49 (1.5) | 69 (2.2) |
| Anaphylaxis | 1 (0.03) | 1 (0.03) |
| Absence from work (no. of days) | .. | |
| no absence | 3183 (97.8) | 2555 (80.7) |
| 1 day | 48 (1.5) | 461 (14.6) |
| 2–3 days | 6 (0.2) | 137 (4.3) |
| 4–5 days | 9 (0.3) | 6 (0.2) |
| ≥6 days | 8 (0.2) | 6 (0.2) |